Want to see IN:GRANULES full AI Analyst Report?
GRANULES Stock Chart & Stats
₹615.10
₹1.80(0.30%)
At close: 4:00 PM EST
₹615.10
₹1.80(0.30%)
Day’s Range― - ―
52-Week Range₹433.00 - ₹840.00
Previous CloseN/A
Volume528.44K
Average Volume (3M)56.05K
Market Cap
₹206.45B
Enterprise Value₹189.35B
Total Cash (Recent Filing)₹6.26B
Total Debt (Recent Filing)₹18.07B
Price to Earnings (P/E)33.8
Beta0.86
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)21.14
Shares Outstanding247,796,920
10 Day Avg. Volume60,875
30 Day Avg. Volume56,048
Financial Highlights & Ratios
PEG Ratio1.39
Price to Book (P/B)2.97
Price to Sales (P/S)2.81
P/FCF Ratio125.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.2
Revenue Forecast (FY)₹62.39B
Bulls Say, Bears Say
Bulls Say
Vertical Integration & ScaleVertical integration across APIs, PFIs and FDF gives Granules manufacturing scale, lowers per‑unit costs, secures upstream supply and creates customer stickiness. Over months this structural setup supports margin resilience, faster market response and durable competitive advantage.
Revenue RecoveryResumption of revenue growth (+10.9% in FY2026) after two relatively flat years signals demand resilience and improved capacity utilization. Sustained top‑line recovery supports earnings power, amortizes fixed costs and underpins multi‑month planning for capacity and product investments.
Conservative Leverage / Balance SheetReasonable leverage (debt/equity ~0.39–0.43) and steady growth in equity/assets provide financial flexibility to fund expansions, absorb cyclical shocks and invest in regulatory compliance. This durability lowers refinancing risk and supports multi‑month operational planning.
Bears Say
Margin PressureGross profit declining even as revenue rose points to persistent cost or pricing pressure in core products. For a generic manufacturer, sustained margin erosion can result from input inflation, pricing competition or adverse mix, reducing operating leverage and long‑term profitability.
Inconsistent Cash ConversionVolatile free cash flow—moving from negative to very strong and then down ~19%—shows working capital and capex are absorbing earnings. Weak, inconsistent cash conversion limits self‑funding for growth, increases reliance on external capital and constrains strategic flexibility over months.
Declining Returns On EquityROE falling from ~25% to the mid‑teens indicates diminishing capital efficiency and weaker returns on incremental investment. If sustained, lower ROE can curb shareholder value creation and forces management to improve allocation or pursue higher‑return initiatives.
Granules India Limited News
GRANULES FAQ
What was Granules India Limited’s price range in the past 12 months?
Granules India Limited lowest stock price was ₹433.00 and its highest was ₹840.00 in the past 12 months.
What is Granules India Limited’s market cap?
Granules India Limited’s market cap is ₹206.45B.
When is Granules India Limited’s upcoming earnings report date?
Granules India Limited’s upcoming earnings report date is Aug 12, 2026 which is in 38 days.
How were Granules India Limited’s earnings last quarter?
Granules India Limited released its earnings results on Apr 29, 2026. The company reported ₹7.6 earnings per share for the quarter, beating the consensus estimate of ₹6.05 by ₹1.55.
Is Granules India Limited overvalued?
According to Wall Street analysts Granules India Limited’s price is currently Overvalued.
Does Granules India Limited pay dividends?
Granules India Limited pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.24%. See more information on Granules India Limited dividends here
What is Granules India Limited’s EPS estimate?
Granules India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Granules India Limited have?
Granules India Limited has 247,796,920 shares outstanding.
What happened to Granules India Limited’s price movement after its last earnings report?
Granules India Limited reported an EPS of ₹7.6 in its last earnings report, beating expectations of ₹6.05. Following the earnings report the stock price went up 0.078%.
Which hedge fund is a major shareholder of Granules India Limited?
Currently, no hedge funds are holding shares in IN:GRANULES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Granules India Limited
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―